Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials
European Heart Journal - Cardiovascular Pharmacotherapy

Abstract
The aim of this study was to systematically assess the effects of antiplatelets on clinical outcomes in patients with atrial fibrillation (AF), treated and not-treated with oral anticoagulation.
We searched MEDLINE, Embase, and CENTRAL from inception until September 2020. From 5446 citations, we selected randomized trials allocating patients with AF to antiplatelet therapy vs. control. We applied random-effects models for meta-analysis and assessed potential effect modification with background anticoagulation use. Eighteen trials including 21 518 participants met our prespecified eligibility criteria. In 10 studies without background anticoagulation, antiplatelets reduced all-cause stroke [486/6165 (events/patients) vs. 621/6061; risk ratio (RR) 0.77, 95% confidence interval (CI) 0.69–0.86,
In patients with AF not receiving oral anticoagulation, antiplatelet therapy modestly reduced stroke. There was a corresponding signal for harm when used on top of anticoagulation. Irrespective of background anticoagulation use, antiplatelet therapy significantly increased bleeding, moderately reduced myocardial infarction, and did not affect mortality.
Contributors

Isabelle Johansson
Author

Willem J M Dewilde
Author

Renato D Lopes
Author

Roxana Mehran
Author
Icahn School of Medicine at Mount Sinai New York City , United States of America

Samantha Sartori
Author

Nikolaus Sarafoff
Author

Satoshi Yasuda
Author

William F McIntyre
Author

Jeff S Healey
Author

Ashkan Shoamanesh
Author

John W Eikelboom
Author

Stuart J Connolly
Author
You may be interested in


